Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 8/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778720 | 0.95 | PARP1 (0.51) | PARP1DRD4DRD2KCNH2MCHR2 | |
| SCHEMBL3776521 | 0.92 | PARP1 (0.44) | PARP1DRD4DRD2KCNH2MCHR2 | |
| SCHEMBL13063405 | 0.90 | PARP1 (0.47) | PARP1DRD4DRD2KCNH2MCHR2 | |
| SCHEMBL3786876 | 0.89 | HTR1A (0.45) | PARP1DRD4DRD2MMP8MMP13 | |
| SCHEMBL3791058 | 0.87 | CCR2 (0.44) | KCNH2CCR2 | |
| SCHEMBL3783405 | 0.85 | OPRK1 (0.42) | PARP1DRD4DRD2MMP8MMP13 | |
| SCHEMBL3783751 | 0.85 | CCR2 (0.42) | KCNH2CCR2 | |
| SCHEMBL3033924 | 0.83 | CCR2 (0.43) | KCNH2MCHR1CCR2TSHR | |
| SCHEMBL3043761 | 0.81 | CCR2 (0.45) | KCNH2CCR2TSHR | |
| SCHEMBL3023181 | 0.81 | CCR2 (0.45) | KCNH2CCR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | claimed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2009076404-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | PARP1 1013/4885DRD4 2433/4885DRD2 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.